His main research concerns Leukemia, Internal medicine, Myeloid leukemia, Oncology and Myeloid. Martin S. Tallman has researched Leukemia in several fields, including Acute promyelocytic leukemia, Cancer and Adverse effect. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery.
His Myeloid leukemia research integrates issues from Myelodysplastic syndromes, Enasidenib, Fms-Like Tyrosine Kinase 3 and Cellular differentiation. The study incorporates disciplines such as Clinical trial, Pharmacology, Transplantation and Cohort in addition to Oncology. His studies deal with areas such as Daunorubicin and Anthracycline as well as Myeloid.
Martin S. Tallman spends much of his time researching Internal medicine, Oncology, Myeloid leukemia, Leukemia and Cancer research. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. His work deals with themes such as Cancer, Clinical trial and Cohort, which intersect with Oncology.
His studies in Myeloid leukemia integrate themes in fields like Enasidenib, Refractory, Intensive care medicine, Stem cell and Disease. His Leukemia study incorporates themes from Myeloid, Bone marrow and Acute promyelocytic leukemia. His biological study spans a wide range of topics, including Mutation, Haematopoiesis and Mutant.
His scientific interests lie mostly in Internal medicine, Oncology, Myeloid leukemia, Cancer research and Leukemia. Arsenic trioxide and Febrile neutropenia is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Internal medicine. His work on Chemotherapy regimen as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science.
His research integrates issues of Clinical trial, Stem cell, Refractory and Isocitrate dehydrogenase in his study of Myeloid leukemia. His research on Cancer research also deals with topics like
Internal medicine, Myeloid leukemia, Oncology, Gastroenterology and Cancer research are his primary areas of study. Martin S. Tallman regularly ties together related areas like Enasidenib in his Internal medicine studies. The concepts of his Myeloid leukemia study are interwoven with issues in Refractory, Gene mutation, IDH2, IDH1 and Febrile neutropenia.
His research investigates the connection between Oncology and topics such as Chronic lymphocytic leukemia that intersect with problems in Progression-free survival and Cytopenia. His Cancer research study combines topics in areas such as Allosteric regulation, Haematopoiesis, Combination therapy and Myristoylation. His work in Leukemia covers topics such as Myeloid which are related to areas like Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward.
Cancer Cell (2010)
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
Jay P. Patel;Mithat Gönen;Maria E. Figueroa;Hugo Fernandez.
The New England Journal of Medicine (2012)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann.
The New England Journal of Medicine (2017)
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Martin S. Tallman;Janet W. Andersen;Charles A. Schiffer;Frederick R. Appelbaum.
The New England Journal of Medicine (1997)
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Steven L. Soignet;Stanley R. Frankel;Dan Douer;Martin S. Tallman.
Journal of Clinical Oncology (2001)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: